A compound, pharmaceutically acceptable salt, or solvate of Formula I: wherein X is halo, H 2 O, -OC R 9, -P((-CH 2)qCH 3) 3, nitrate or sulfate; wherein q is 0, 1, 2, or 3; X 1 and X 2 are independently halo, C 1-6 alkoxy, C 1-6 alkyl, C 2-6 alkynyl, nitro, amino, -NHC (R 10), -NHC O(R 10), -C NHR 10, or -OC NHR 10; M is Au or Pt and if M is Au, R 1 and R 2 are not present; R 1 and R 2 are amino groups or together with the platinum atom to which they are attached, R 1 and R 2 form the ring -NH 2 -(CH 2) v -NH 2 - wherein v is 1, 2, 3, or 4 or R 1 and R 2 together can be any of the following groups a-h; wherein A is H, -CH 3, -OCH 3, CF 3 or NO 2; R 3 is -N(R 26)- or S; wherein R 26 is hydrogen or C 1 -C 6 alkyl; R4 is hydrogen, C 1-6 alkyl, or CH 2 -R 12; E is -(CH 2) q -; R 5 is a direct bond, -NH- or C 1 -C 6 alkylene; or R 5 and X together with the atoms to which they are attached form a 6- or 7-membered ring, wherein said 6- or 7-membered ring contains a linking group -C O- or -OC -; R 7 is hydrogen, methyl, -CH(R 17)(R 18), -C O-R 18, or - OC -R 18; wherein R 17 is hydrogen or C 1-6 alkyl; R 18 is hydrogen, C 1-6 alkyl, -CH(R 19)(R 20), phenyl, naphthyl, C 3-6 cycloalkyl, norbornyl, adamantyl, a natural or unnatural amino acid or a peptide; R 19 is hydrogen or C 1-6 alkyl; R 20 is hydrogen, C 1-6 alkyl; R 8 is -NR 13 -, -C NR 13 -, -NR 13 C -, -O-, -S-, -OC -, and -C O-R 13 is -H or -C 1-6 alkyl; R 9 is hydrogen, C 1-6 alkyl, phenyl, naphthyl, C 3-6 cycloalkyl, norbornyl, adamantyl, a natural or unnatural amino acid or a peptide; R 11 and R 12 are independently hydrogen, hydroxyl, C 1-6 alkyl, -OCH 3,-CF 3, NO 2; and Z is independently one or more halo or nitro, or one or more counterions sufficient to balance the charge of the compound. wherein X is halo, H 2 O, -OC R 9, -P((-CH 2)qCH 3) 3, nitrate or sulfate; wherein q is 0, 1, 2, or 3; X 1 and X 2 are independently halo, C 1-6 alkoxy, C 1-6 alkyl, C 2-6 alkynyl, nitro, amino, -NHC (R 10), -NHC O(R 10), -C NHR 10, or -OC NHR 10; M is Au or Pt and if M is Au, R 1 and R 2 are not present; R 1 and R 2 are amino groups or together with the platinum atom to which they are attached, R 1 and R 2 form the ring -NH 2 -(CH 2) v -NH 2 - wherein v is 1, 2, 3, or 4 or R 1 and R 2 together can be any of the following groups a-h; wherein A is H, -CH 3, -OCH 3, CF 3 or NO 2; R 3 is -N(R 26)- or S; wherein R 26 is hydrogen or C 1 -C 6 alkyl; R4 is hydrogen, C 1-6 alkyl, or CH 2 -R 12; E is -(CH 2) q -; R 5 is a direct bond, -NH- or C 1 -C 6 alkylene; or R 5 and X together with the atoms to which they are attached form a 6- or 7-membered ring, wherein said 6- or 7-membered ring contains a linking group -C O- or -OC -; R 7 is hydrogen, methyl, -CH(R 17)(R 18), -C O-R 18, or - OC -R 18; wherein R 17 is hydrogen or C 1-6 alkyl; R 18 is hydrogen, C 1-6 alkyl, -CH(R 19)(R 20), phenyl, naphthyl, C 3-6 cycloalkyl, norbornyl, adamantyl, a natural or unnatural amino acid or a peptide; R 19 is hydrogen or C 1-6 alkyl; R 20 is hydrogen, C 1-6 alkyl; R 8 is -NR 13 -, -C NR 13 -, -NR 13 C -, -O-, -S-, -OC -, and -C O-R 13 is -H or -C 1-6 alkyl; R 9 is hydrogen, C 1-6 alkyl, phenyl, naphthyl, C 3-6 cycloalkyl, norbornyl, adamantyl, a natural or unnatural amino acid or a peptide; R 11 and R 12 are independently hydrogen, hydroxyl, C 1-6 alkyl, -OCH 3,-CF 3, NO 2; and Z is independently one or more halo or nitro, or one or more counterions sufficient to balance the charge of the compound.